• Home
  • Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

The impact of China’s latest covid-19 surge heads the latest quarterly in-vitro diagnostics (IVD) market data. Point-of-care (POC) testing for infectious diseases is emerging as the best-performing market segment in Q2 2022, based on the latest data and analysis from Economist Intelligence Clearstate’s Quarterly Company Insights (QCI) for China.

“The POC testing market maintained strong growth in this quarter. Cardiac POC testing increased in the quarter due to the opening of a nationwide chest pain centre. Multiple outbreaks of the omicron variant across the country also drove up the demand for POC blood gas testing, and POC SARS-CoV-2 antigen tests,” said David Liu, manager for MedTech Market Tracker Solutions.

Understand the China IVD market and your competition with QCI

  • Policy highlights: China policy remains challenging for IVD multinationals (MNCs). “Document 551” has squeezed public hospitals’ procurement of imported instruments, while supply-chain disruptions caused by transportation restrictions in pursuit of “Covid Zero”, resulted in a shortage of reagents to lockdown-affected cities. Amendments to the China Government Procurement Law have made a series of critical changes, including further standardisation of the scoring mechanism and support for domestic brands.
  • Core lab market: reduced testing and falling sales is evident in the market as a result of intensified mobility restrictions, with multiple outbreaks of the Omicron variant in major Chinese cities.
  • Point-of-care (POC) testing market: strong quarterly growth is seen in China’s POC testing market as a result of an increase in cardiac, blood gas and SARS-CoV-2 antigen tests, as covid-19 outbreaks drove demand for blood gas and SARS-CoV-2 tests.
  • Molecular diagnostics (MDx) market: the overall MDx market in Q2 2022 has grown, largely driven by SARS-CoV-2 PCR testing. Routine Sars-CoV-2 PCR tests continue to be required in major Chinese cities including Beijing, Shanghai, Shenzhen and Chengdu. However, test prices have taken a hit from the volume-based procurement (VBP) policy and falling prices of SARs-CoV-2 PCR have reduced the momentum of revenue growth in the area.
  • Tissue diagnostics (TDx) market: organic growth has maintained despite covid-19 outbreaks. However, the focus on covid-19 prevention in some hospitals has shifted budget allocation, holding up some pathology instrument purchase plans for the first half of 2022.

Understand the China IVD market and your competition with QCI 

Quarterly Company Insights (QCI) for China—which tracks and monitors the quarterly market performances and activities of top IVD companies, provides the latest quarter updates on top market and player activities in the core lab, molecular diagnostics (MDx) and point-of-care (POC) testing and tissue diagnostics (TDx) market segments.

The second update on Q2 2022 is now available.

QUARTERLY COMPANY INSIGHTS

Quarterly Company Insights (QCI) provides in-depth reports on China’s top IVD companies’ localised commercial activities in core labs, point-of-care testing, molecular and tissue diagnostics to help you understand the key players’ dynamics in the world’s largest emerging IVD market.

Find out more